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Abstract Multiple myelomas (MMs) are etiologically
heterogeneous and there are limited treatment options;
indeed, current monoclonal antibody therapies have had
limited success, so more effective antibodies are urgently
needed. Polyclonal antibodies are a possible alternative
because they target multiple antigens simultaneously. In
this study, we produced polyclonal rabbit anti-murine
plasmacytoma cell immunoglobulin (PAb) by immunizing
rabbits with the murine plasmacytoma cell line MPC-11.
The isolated PAb bound to plasma surface antigens in
several MM cell lines, inhibited their proliferation as
revealed by MTT assay, and induce apoptosis as indicated
by ﬂow cytometry, microscopic observation of apoptotic
changes in morphology, and DNA fragmentation on aga-
rose gels. The cytotoxicity of PAb on MPC-11 cell lines
was both dose-dependent and time-dependent; PAb exerted
a 50% inhibitory effect on MPC-11 cell viability at a
concentration of 200 lg/ml in 48 h. Flow cytometry
demonstrated that PAb treatment signiﬁcantly increased
the number of apoptotic cells (48.1%) compared with
control IgG (8.3%). Apoptosis triggered by PAb was
conﬁrmed by activation of caspase-3, -8, and -9. Serial
intravenous or intraperitoneal injections of PAb inhibited
tumour growth and prolonged survival in mice bearing
murine plasmacytoma, while TUNEL assay demon-
strated that PAb induced statistically signiﬁcant apoptosis
(P\0.05) compared to control treatments. We conclude
that PAb is an effective agent for in vitro and in vivo
induction of apoptosis in multiple myeloma and that
exploratory clinical trials may be warranted.
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Introduction
Multiple myeloma (MM) accounts for approximately 10%
of malignant hematologic neoplasms, and is resistant to
conventional chemotherapy, high-dose radiotherapy,
autologous stem cell transplantation, and allogeneic trans-
plantation [1, 2]. A promising alternative strategy is the
development of speciﬁc immunotherapies selectively tar-
geting myeloma cells [3]. A variety of tumour-associated
antigens have been identiﬁed in myeloma cells, including
CD20, CD40, CD52, MUC1, HM1.24, CYP1B1, SP17,
PRAME, WT1, and heat shock protein gp96 [4–7]. In fact,
an anti-CD20 monoclonal antibody, marketed as Ritux-
imab, is already commercially available [8]. In addition,
some monoclonal antibody therapies have progressed into
clinical trials, including SGN-40 (anti-huCD40 MoAb) [9],
anti-CD52 (alemtuzumab) [10], MRA (atlizumab), TRM-1
(Full Human TRAIL-R1 MoAb), AHM (anti-HM1.24
MoAb) [11], and anti-CD126 (atlezumab) [12].
Unfortunately, myeloma cells are a heterogeneous
population that express numerous cell surface antigens,
including CD38, CD45, CD138, and adhesion molecules
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DOI 10.1007/s10495-010-0568-7like VLA4 [13]. Different patients express different arrays
of antigens; for example, CD20 can be detected in only
13–22% of patients [14]. Furthermore, multiple myeloma
cells manifest intrinsic genetic mechanisms of drug resis-
tance [15], further limiting treatment success, including
that from available monoclonal antibodies. Targeting
multiple antigens at the same time is a possible alternative
but one that obviously requires the isolation and testing of
efﬁcient polyclonal antibodies.
Previous research suggested that polyclonal antibodies
are a promising tumour therapy. For example, treating
different myeloma cell lines with polyclonal rabbit anti-
thymocyte globulin rATG resulted in speciﬁc activity
against various surface proteins expressed on myeloma
cells, such as CD19, CD20, CD27, CD38, CD126, and
CD138, and induce signiﬁcant apoptosis in myeloma cell
lines by multiple pathways in vitro [16]. In addition, the
rabbit-derived polyclonal anti-thymocyte globulin (thy-
moglobulin) targeted multiple plasma cell antigens in vitro
and in vivo [13]. Although ATG (anti-thymocyte globulin)
or ALG (anti-lymphocyte globulin) are produced by
immunizing horses or rabbits with human thymocytes or
activated T-cell or B-cell blasts, myeloma cells are actually
terminally differentiated as neoplastic B cells with a low
proliferative index and a long life span, so ATG or ALG
alone may be inadequate for patients with a high myeloma-
cell burden. Aside from immunocytes, myeloma cells can
be used as the immunogen to prepare polyclonal antibod-
ies. Indeed this strategy may be more speciﬁc and efﬁcient
because surface antigens were present in mouse myeloma
cells but were not detected on cells of other tissues [17].
Inthisstudy,weisolatedPAbbyimmunizingrabbitswith
murine MPC-11 plasmacytoma cells,a cellline that shares a
number or common features with human MM cells [18]. We
found that PAb could inhibit proliferation and induce
apoptosis of multiple myeloma cell lines in vitro, and
induced apoptosis after serial intravenous or intraperitoneal
injection of PAb in mice carrying murine plasmacytoma in
vivo. We observed tumour growth delay and prolonged
survival relative to mice treated with a control IgG. These
results suggest that broad speciﬁcity of polyclonal IgG may
be related tomultiple targets on multiple myeloma cells. We
conclude that PAb is an effective agent for in vitro and in
vivo induction of apoptosis in multiple myeloma and that
exploratory clinical trials may be warranted.
Materials and methods
Animals and cell lines
New Zealand white rabbits and 6–8 week old BALB/c
mice were purchased from the West China Experimental
Animal Center. Animal protocols for these experiments
were approved by the West China Hospital Cancer Cen-
ter’s Animal Care Committee. In this study, the murine
plasmacytoma cell lines MPC-11, SP2/0, and NS-1, along
with the murine colon carcinoma cell line CT26 and
murine melanoma cell line B16 were obtained from the
American type culture collection (ATCC). Cells were
cultured in RPMI-1640 (Gibco) containing 10% heat-
inactivated foetal calf serum (FCS; Gibco) with 100 units/
ml penicillin, and 100 units/ml streptomycin, in a humid-
iﬁed 5% CO2 incubator at 37C.
Rabbit immunizations and preparation of PAb
The PAb polyclonal antibody was generated by immuniz-
ing New Zealand white rabbits with MPC-11 cells using
1 9 to 5 9 10
7 per injection. The primary inoculation was
with Freund’s complete adjuvant (Sigma), followed by
three boosts with Freund’s incomplete adjuvant (Sigma)
once every 10–14 days. The serum was pooled a week after
the last injection. Blood was allowed to clot overnight at
4C and serum was removed from the top of the mixture
after centrifugation at 120009g. Immunoglobulin was
isolated using an afﬁnity chromatography system (AKTA
explore, GE, USA) and freeze dried (Rlphr 1–4 LSC freeze
drier, Christ, German). Antibodies were kept frozen at
-80C until used. Control rabbit IgG was similarly puriﬁed
from whole normal rabbit serum.
ELISA
For ELISA assays, MPC-11 cells were grown overnight in
thewellsofpoly-lysine-coated96-wellplates(5 9 10
3 cells/
well). The media was removed and the cells were washed
three times in PBS. After washing, the cells were blocked
with 5% skim milk in blocking buffer (PBS containing
0.05% Tween-20 or PBST) for 1 h at room temperature. The
blocking reagent was removed and the cells were washed
three times in PBS before the PAb was added. The PAb was
added at 0.25–2.5 lg/ml in dilution buffer (5% skim milk in
PBST) and cells were incubated for 1 h at room temperature.
The antibody was removed and the cells were washed three
times in PBST. The secondary goat anti-rabbit antibody
linkedtoalkalinephosphatase(1:5000,Sigma)wasaddedfor
30 min. The cells were then washed three times in PBST.
Subsequently, alkaline phosphatase substrate BCIP/NCP
(Sigma) was added and absorbance was measured at 450 nm
using a 96-well plate reader (Molecular Devices, M5, USA).
Immunoﬂuorescence stain of multiple myeloma cells
Thetumourcelllineslistedaboveweregrowntologarithmic
phase, harvested, and washed three times with PBS. Cell
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123lines were blocked with 5% skim milk in PBST for 1 h at
room temperature. The blocking reagent was removed and
1:1000 PAb or control rabbit IgG in PBST containing 5%
skimmilkwasaddedfor30 min.Theantibodywasremoved
and the cells were washed three times in PBST. The sec-
ondary FITC-goat anti-rabbit IgG antibody (1:500; Beijing
Zhong Shan-Golden Bridge Biological Technology CO.,
LTD, China) was added and incubated for 30 min. Cells
were washed three times in PBST and 10,000 cells were
harvested for ﬂow cytometry. (Beck-man-coulter, USA).
Localization of PAb binding with antigens on multiple
myeloma cells
Cultured MPC-11 cells at 5 9 10
6 per well were ﬁxed for
5 min with 100 ll 4% formaldehyde in phosphate-buffered
saline at pH 7.6; 30 ll of the ﬁxed cell suspension was
spread on microscope slides for cell smears. After drying,
cells were permeated by treatment for 5 min with 0.5%
Triton X-100 in buffer containing 10 mM Hepes, 300 mM
sucrose, 3 mM MgCl2, and 50 mM NaCl, pH 7.4. Cells
were incubated with PAb or control rabbit IgG (dilution of
1:1000) overnight at 4C. The antibody was removed and
the cells were washed three times in PBST. The secondary
FITC-goat anti-rabbit IgG antibody (1:500; Beijing Zhong
Shan-Golden Bridge Biological Technology CO., LTD,
China) was added and cells were incubated in a humidiﬁed
chamber for 30 min. The antibody was removed and the
cells were washed three times in PBST, stained with
Hoechst33258 for 5 min, washed with PBS, and imaged
under a ﬂuorescent microscopy (Zeiss Photoscope Imager).
Cell viability analysis
Cell viability analysis was determined by 3-(4,5-dimethyl-
thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT,
Sigma)assay.Brieﬂy,culturedMPC-11cells,normalmouse
spleen cells, or B and T cells puriﬁed from splenocytes by
nylon wool column [19], were seeded in 96-well plates at a
volume of 100 ll per well and incubated for 24 h. The cells
were treated with normal saline (NS), control rabbit IgG, or
with PAb for 24, 48, or 72 h at 37C. The MTT assay was
then performed by dissolving the reaction product in DMSO
and measure the absorbance at 540 nm. The cells treated
with NS served as the control indicator of 100% cell via-
bility. For caspase inhibition, cells were incubated with the
general caspase inhibitor zVAD-fmk (100 lM) for 1 h prior
to addition of PAb and then cultured for 48 h as above.
Apoptosis analysis by DNA fragmentation assay
The MPC-11 cells were incubated in RPMI1640 medium
for 20 h with the agents indicated. DNA preparations were
obtained by following a previously described procedure
[20]. Brieﬂy, MPC-11 cells (5 9 10
6) were lysed in 0.5 ml
lysis buffer containing 5 mM Tris–HCl (pH 8), 0.25%
Nonidet P-40, 1 mM EDTA, and 200 lg/ml RNaseA
(Sigma) and incubated at 37C for 1 h. Cells were then
treated with proteinase K at a concentration of 300 lg/ml
for 1 h at 37C. Following the addition of 69 loading
buffer, 25 ll lysate samples were subjected to electro-
phoresis on 1.5% agarose gels at 50 V for 3 h. DNA was
stained with gold view (Sigma).
Apoptosis analysis by ﬂow cytometry assay
The MPC-11 cells (3 9 10
5) were plated in 6-well plates
and treated with normal saline, control IgG (200 lg/ml), or
PAb (200 lg/ml). After 48 h, ﬂow cytometric analysis was
performed to detect G1 cells and apoptotic cells. Brieﬂy,
cells were suspended in 1 ml hypotonic ﬂuorochrome
solution containing 50 lg/ml propidium iodide in 0.1%
sodium citrate plus 0.1% Triton X-100, and analyzed by a
ﬂow cytometer. Apoptotic cells were deﬁned as cells with
DNA content less than that of G1 phase cells in the cell
cycle distribution.
Western blotting
The activation of caspase-3, -8, and -9 were determined by
Westernblotting.TheMPC-11cells(3 9 10
5)we repl at edin
6-wellplatesandtreatedwithNS,controlIgG(200 lg/ml),or
PAb(200 lg/ml).After48 h,cellsfromeachtreatmentgroup
werelysedinbuffer(2 9 PBS,0.1%SDS,1%NonidetP-40,
0.5% sodium deoxycholate, and 0.1 mM phenylmethylsul-
fonyl ﬂuoride), and then homogenized with an ultrasonic
homogenizer. Proteins (25 lg/lane) were separated by SDS–
PAGE. The separated proteins were transferred to polyvi-
nylidene ﬂuoride (PVDF)membranes byelectroblotting.The
membranes were blocked in 5% (w/v) skim milk in TBST
(20 mM Tris, 500 mM NaCl, 0.1% Tween-20, pH 7.6), and
incubated overnight at 4C with primary antibodies for cas-
pase-3 (Cell Signaling Technology), anti-murine caspase-8
(ThermoScientiﬁc),oranti-murinecaspase-9(CellSignaling
Technology). The membrane was then washed three times
with TBST and incubated with a secondary antibody conju-
gatedwithhorseradishperoxidaseata1:5000dilutionfor1 h,
followed by visualization with Vectastain ABC (Vector
Laboratories, Burlingame, CA).
Antitumour effect of PAb to mouse models established
with MCP-11 cells
Two tumour mouse models were developed. Tumours were
established by either a single subcutaneous (s.c.) injection
of 2 9 10
5 MPC-11 tumour cells into the right ﬂank or one
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123intraperitoneal (i.p.) injection of 2 9 10
6 MPC-11 tumour
cells. Treatments were initiated on the seventh day after
tumour cell inoculation in the s.c. tumour model (a time
when tumour nodules were palpable), or on the ﬁfth day
after tumour cell inoculation for the i.p. tumour model. All
animals were randomized into three groups with six mice
per group, and administered PAb (200 lg/dose), control
IgG (200 lg/dose) or NS once every two days in a volume
of 100 ll, for a total of seven administrations. The s.c.
tumour model mice were treated via tail vein injection and
the mice in the i.p. tumour model group received treatment
by intraperitoneal injection. The volume of a subcutaneous
tumour nodule was calculated as length 9 breadth
2/2, and
the intraperitoneal nodules were counted using a dissecting
microscope.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
Cell apoptosis in vivo was investigated using a terminal
deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) assay according to the manufacturer’s
instructions (Promega, USA). Three tumour nodules per
group in the s.c. tumour model were analyzed at 48 h after
the last treatment.
Statistical analysis
The statistical signiﬁcance of results in all of the experi-
ments was determined by Student’s t test and ANOVA
using SPSS 13 analysis software. Findings were regarded
as signiﬁcant if P\0.05.
Results
Production and characterization of PAb
There was about 3–10 fold greater binding of PAb to MPC-
11 cells compared with control IgG and binding efﬁcacy
was dose-dependent over the range of 0.25–2.5 lg/ml PAb
(Fig. 1a). We analysed binding of PAb to the plasma
membrane of multiple myeloma cell surface antigens by
ﬂow cytometry and ﬂuorescence microscopic analysis. The
polyclonal antibody was much more effective at recog-
nizing surface antigens than control IgG in MPC-11 murine
myeloma cells, as well as in SP2/0 and NS-1 cells. How-
ever, PAb did not bind non-myeloma cell lines, such as the
murine colon carcinoma cell line CT26 and murine mela-
noma cell line B16 (Fig. 1b, c). These results demonstrate
that PAb polyclonal antibodies speciﬁcally targeted mye-
loma cells.
PAb inhibited myeloma cell proliferation
We ﬁrst determined the effect of PAb on growth of MM
cell lines using the MTT assay in the presence or absence
of PAb. As shown in Fig. 2, PAb reduced cell number in a
dose-dependent and time-dependent manner. The dose-
response and time-dependent curves (Fig. 2a) revealed that
PAb at concentrations of 200 lg/ml or greater were most
effective at reducing the cell number. The maximum effect
was seen at 72 h incubation with only slightly lower
activity at 48 h. Similar results were obtained from NS-1
and SP2/0 cell lines (data not shown) suggesting that PAb
could reduce cell number by inhibiting proliferation or by
inducing cytotoxicity in multiple myeloma cell lines. As
these cells proliferate slowly, cytotoxicity was the most
likely mechanism and was investigated in subsequent
experiments.
To determine whether complement derived from FCS in
the culture medium could contribute to the observed
cytotoxicity, we repeated these experiments using non-heat
inactivated (complement-containing) FCS (Fig. 2b). These
experiments suggested that both complement-mediated and
complement-independent mechanisms contributed to the
observed reduction in MM number. In the absence of
detectable complement activity, MPC-11 cell proliferation
was inhibited by up to 56.3% at 200 lg/ml PAb (P\0.05;
Fig. 2a), and similar results were also shown in NS-1 and
SP2/0 cell lines (data not shown). All subsequent experi-
ments were performed using heat-inactivated FCS to fur-
ther characterize the complement-independent mechanisms
of MM cytotoxicity induced by PAb. In addition, we found
that PAb did not effect the growth of normal mixed pop-
ulations of splenocytes (Fig. 2c). We also puriﬁed B and T
cells from splenocytes by nylon wool column and found
that PAb did not inhibit these immunocytes (Fig. 2c).
PAb induced apoptosis of myeloma cells
A decrease in myeloma cell proliferation may also result
from the induction of apoptosis, so we determined whether
PAb induced apoptosis using light microscopy, ﬂow
cytometry, and DNA fragmentation analysis. The PAb-
treated MM cells appeared morphological distinct from
controls, with condensation of the cytoplasm and mem-
brane blebbing (Fig. 3a–c). In addition, agarose gel elec-
trophoresis demonstrated that PAb-treated cells exhibited
a ladder-like pattern of DNA fragments consisting of
multiples of approximately 180–200 bp, consistent with
endonuclease-induced DNA fragmentation (Fig. 3d). Fur-
thermore, ﬂow cytometry indicated that PAb treatment
signiﬁcantly increased the number of apoptotic cells
compared with the control treatments (PAb-treated, 48.1%;
NS-treated, 7.0%; control Rabbit IgG-treated, 8.3%)
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123(Fig. 3E). To conﬁrm that PAb induced apoptosis of
myeloma cells, we examined the activation of caspases-3,
-8, and -9 by Western blotting (Fig. 3f). Indeed, treatment
with PAb led to increased enzyme activities of these
caspases at 48 h post-treatment and ultimately causing
apoptosis by DNA fragmentation. In addition, the broad-
spectrum caspase inhibitor of z-VAD-fmk inhibited PAb-
induced MPC-11 cell death (Fig. 3g), conﬁrming that
caspases are activated following PAb treatment and are
necessary for apoptosis in MPC-11cells. Thus, PAb
inhibited proliferation and induced apoptosis in a myeloma
cells in vitro.
PAb reduced tumour growth in an animal model
of myeloma
To examine the anti-tumour activity of PAb in vivo,
6–8 week-old Babl/c mice were injected with MPC-11
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123cells subcutaneously or intraperitoneally as described in the
methods section. On necropsy, analysis of abdominal
contents revealed large multiple large tumour nodules in
NS and control IgG-treated mice. The number of visible
tumour nodes (NS, 35 ± 6.4; control IgG, 46.3 ± 6.3) was
drastically reduced in PAb-treated mice (4.2 ± 6.1)
(Fig. 4). Tumour size were similar in both control
groups (NS-treated, 1.4 ± 0.6 cm
3; control IgG-treated,
1.5 ± 0.8 cm
3) and were principally dispersed around the
small bowel with sparsely seeding on at mesentery and
diaphragm. In contrast, the abdominal contents from the
PAb treated group showed smaller (0.6 ± 0.3 cm
3) tumour
nodules localized to small bowel mesentery. The results
showed that treatment with PAb resulted in a signiﬁcant
inhibition of tumours growth compared with NS treatment
(P\0.01) and control IgG treatment (P\0.05).
To assess the long-term antitumour effect of PAb, sub-
cutaneous MPC-11 cell implantations were developed to
study tumour growth through measurement of their vol-
umes in vivo. The results showed that the treatment with
PAb resulted in a signiﬁcantly increased regression of
established tumours as compared with treatment with NS
or control IgG (Fig. 5). The average tumour volume in the
PAb group was stable for the duration of administration,
but the average tumour volume in the NS and control IgG
groups still grew after (sham) treatment. The inhibition rate
was 61.6% relative to the NS group and 65.2% compared
with the control IgG group (Fig. 5a). In addition, treatment
with PAb resulted in a signiﬁcantly decreased tumour
weight compared with treatment with NS or control IgG
(P\0.05, Fig. 5b). Furthermore, survival was also sig-
niﬁcantly prolonged when MPC-11-bearing mice were
treated with PAb. The median survival in the NS group was
32 days and treatment with control IgG did not prolong
mice survival further. In contrast, median survival in MPC-
11 bearing mice with PAb treatment increased to more than
60 days (Fig. 5c). Thus, PAb possessed anti-tumour
activity in vivo. In order to test whether apoptosis was the
mechanism by which PAb produced anti-tumour effects in
vivo, we performed a TUNEL assay on histological sec-
tions. As shown in Fig. 6, there were more apoptotic cells
(with green nuclei) in tumour tissues from PAb treated
B 
C
A 
0
20
40
60
80
100
120
10
20
50
100
200
500
1000
PAb Conc(μg/ml)
c
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
24h
48h
72h
0
20
40
60
80
100
120
10
20
50
100
200
500
1000
PAb Conc (μg/ml)
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
24h
48h
72h
0
20
40
60
80
100
120
spleen cell T cell B cell
c
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
NS
Control IgG
PAb
Fig. 2 The PAb polyclonal
antibody was cytotoxic to the
myeloma cell MPC-11 line.
a MPC-11 cells were cultured
with or without PAb in medium
containing inactivated FCS at
37C for 24, 48, or 72 h. Cell
viability was measured by a
colorimetric assay utilizing
MTT. b MPC-11 cells were
cultured with or without PAb in
medium containing FCS at 37C
for 24, 48, or 72 h and cell
viability was measured MTT.
c MTT analysis of normal mice
spleen cells and puriﬁed B and
T cells from splenocytes treated
with PAb
Apoptosis (2011) 16:370–381 375
123mice than from either control IgG and NS treated mice
(P\0.05).
Discussion
The clinical efﬁcacies of conventional MM therapies,
including chemotherapy, high-dose radiotherapy, or allo-
geneic stem cell transplants are poor due to the heteroge-
neity of MMs, the presence of drug-resistance mechanisms,
and the structural complexity of tumours within connective
tissue [21]. Immunotherapy based on antibodies offers a
possible alternative to cure malignancy [22]. Targeting cell
surface antigens using monoclonal antibodies represents a
very attractive approach [23]. Rituximab demonstrated
impressive clinical responses and became the ﬁrst mAb
approved by the FDA for use in human malignancy [24].
Some other promising antibodies have also been evaluated
in preclinical and clinical studies [14, 25–28]. However, no
universal target common to all myeloma cells has been
found and patients express different sets of surface anti-
gens. Therefore, no one monoclonal antibody will be
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123effective in all patients [29], while drug resistance will
eventually may hamper chemotherapy [15, 30]. Present
monoclonal antibody therapies are not optimal and more
effective antibodies are urgently needed.
Polyclonal antibodies are a possible alternative as they
possess several inherent advantages. First, polyclonal
antibodies raised against a selected target in hyper-immu-
nized animals recognize the most immunogenic epitopes
and so are ‘naturally selected’ for by the host [29]. This
may also permit the development and manufacture of
polyclonal antibodies that recognize multiple surface pro-
teins and simultaneously activate multiple biochemical
pathways leading to cell death. Second, polyclonal anti-
body therapeutics may be advantageous due to the high
density of antibodies binding to the tumour cell surface.
This would promote enhanced cross-linking of Fc receptors
on effectors cells and efﬁcient C1q binding in immuno-
deﬁcient patients [31]. Finally, the PAb could preclude the
development of tumour cell ‘‘escape variants’’, because the
probability that tumour cells will simultaneously lose all
target epitopes is extremely small.
Two available polyclonal antibodies, ATG or ALG,
were obtained by immunizing horses or rabbits with human
thymocytes or activated T- or B-cell blasts. One potential
problem with this strategy is that the relative
concentrations of B-cell and T-cell antibodies in the
polyclonal antibody preparations have not been deter-
mined. It is therefore possible that the clinical anti–mye-
loma cell activity of ATG may be inadequate to deal with
patients with high myeloma-cell burdens. On the other
hand, there is a risk of infection with ATG therapy in
myeloma due to its ability to deplete the T-cell count.
Infections related to T-cell depletion tend to be of viral
origin, including Epstein-Barr virus, adenovirus, cyto-
megalovirus, parvovirus, and herpes viruses [16]. Com-
pared with these polyclonal antibodies, our PAb may be an
improvement because PAb was obtained by immunizing
rabbits with whole living murine multiple myeloma cells.
To our knowledge, this is the ﬁrst time that PAb has been
produced by immunizing rabbits with whole living tumour
cells as antigens. An additional advantage is that all the
molecules on the tumour cells, including unknown mole-
cules, are exposed to the immune system. In addition, only
surface antigens present in mouse myeloma cells will
evoke an immune response, not antigens expressed by
beneﬁcial immunocytes or other cells [17]. Our antibody
had high speciﬁcity for MM cells, could recognize multiple
epitopes simultaneously, and showed low binding to non-
tumour cells. This allowed PAb to kill tumour cells at
relatively low doses. Our study also conﬁrmed that PAb
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123signiﬁcantly inhibited growth and induced apoptosis in
myeloma cells, but normal spleen cells and puriﬁed B and
T cells from splenocytes were not killed by PAb treatment
(Fig. 2c). These results underscore the speciﬁcity of this
technique and indicate that PAb will not induce
immunosuppression.
A number of studies have shown that cells undergoing
apoptosis have typical biochemical and morphological
patterns, such as condensation of the cytoplasm, membrane
blebbing, and endonuclease-induced DNA fragmentation
[32–35]. Here we demonstrated that PAb induced apoptosis
in multiple murine myeloma cell lines was accompanied by
the usual hallmarks of apoptosis as revealed by micro-
scopic study of changes in cell morphology, DNA ladder-
ing, and ﬂow cytometry (Fig. 3). Furthermore, PAb
delayed tumour growth and prolonged life span by in mice
bearing murine plasmacytoma (Fig. 5). Histological of
TUNEL-stained tumour sections showed that PAb was able
to induce statistically signiﬁcant apoptosis (P\0.05)
compared to control treatments (Fig. 6) and reduce tumour
volume (Fig. 5).
Previous studies have implicated a number of different
mechanisms in the anti-myeloma activity of polyclonal
antibodies like rATG and ALG. A role for complement was
suggested by results that showed enhanced cytotoxicity of
thymoglobulin when cells were incubated in the presence of
complement [36]. In our study, PAb also inhibited prolif-
eration of MM in the presence of complement (Fig. 2b);
however, the cytotoxic effects on myeloma cells were also
observed in the absence of complement (Fig. 2a). The
importance of the caspases in tumour cell death has been
highlighted in complement-independent anti-MM cell via-
bility assays that demonstrated signiﬁcant rescue in the
presence of caspase inhibitors. In our study, we showed that
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on tumour growth in a mouse
model injected subcutaneously
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decrease in tumour size was
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123exposure to PAb decreased procaspase-8 expression and
increased caspase-3 and -9 activities in MPC-11 (Fig. 3f),
which suggested that the mechanism of apoptosis involved
caspases activation. This was supported by results demon-
strating that pre-treatment with the pan-caspase inhibitor
zVAD-fmk decreased apoptosis induced by PAb (Fig. 3g).
Most importantly, we found that PAb was inhibitory
toward murine plasmacytoma cells while the growth of
normal murine spleen cells (B and T cells) was not
inhibited (Fig. 2). These results suggest that our PAb could
bind to speciﬁc multiple myeloma cell receptors resulting
in apoptosis, while allowing immmunocytes (presumably
free of PAb antigens) to assist in anti-tumour activity.
Furthermore, spleen and lymph nodes are probably less
efﬁcient than myeloma tissue because plasma cells com-
prise only a small fraction of the total cell population in
these organs [17].
Though the nature of the antigens recognized by the
PAb is yet not known, Western blotting revealed several
bands in multiple myeloma cell lines lysates (data not
shown). Previous studies demonstrated that both ATG [16]
and thymoglobulina [13] could recognize myeloma cell-
surface proteins linked to apoptotic and growth factor-
receptor pathways, including HLA-ABC, HLA-DR, CD32
(FcRc2), CD19, CD20, CD30, CD38, CD95, CD126
(IL-6R), and CD138. We presume that the anti-myeloma
activity was caused by PAb binding to at least some of
these cell-surface molecules.
In summary, our results indicate that PAb can decrease
tumour growth by binding multiple surface antigens on
myeloma cells and promoting apoptosis. The results
reported here suggest that PAb may have utility as a
component of a clinical regimen for myeloma malignan-
cies. Further careful clinical study will be needed to
examine this possibility, although we conﬁrmed that PAb
can inhibit MM cell proliferation in mammals in vivo.
Response to PAb therapy may vary among patients as
clonal sensitivity to the multiple apoptosis pathways varies.
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123In addition, the marrow microenvironment may afford
additional protection from PAb-induced apoptosis or
complement-mediated lysis. We would suggest that any
trial design include a component of in vitro and in vivo
screening before PAb administration.
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